Post-Polio Syndrome Clinical Trial
Official title:
"Treatment With L-citrulline in Patients With Post-polio Syndrome - a Randomized Double Blind Placebo Controlled Study"
The purpose of the study is to show that the intake of L-citrulline improves muscle function in patients with Post-Polio Syndrome (PPS).
This is a single center, randomized, double-blind, placebo controlled study. The study
medication consists of L-citrulline, respectively placebo given orally; 5 g L-citrulline or
placebo will be given three times daily. The duration of the study is 48 weeks and
comprehends one screening and four study visits.
Additionally, in order to investigate whether PPS is associated with an atrophy of spinal
cord gray and potentially also white matter as well as motor cortex atrophy, it is planned to
offer all trial participants an additional optional spinal cord/brain MRI investigation and a
MRI at week 48 and a follow-up one year later together with a clinical and physiotherapy
assessment during extension phase. We don't expect Citrulline to affect the spinal cord gray
or white and gray matter.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02176863 -
Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03561623 -
Spinal Cord Gray Matter Imaging in Post Polio Syndrome
|
||
Completed |
NCT02815878 -
Enhance Wellness for Individuals With Long-Term Physical Disabilities
|
N/A | |
Recruiting |
NCT05644522 -
Nomad P-KAFO Study
|
N/A | |
Completed |
NCT03064711 -
Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics in Post-Polio Patients
|
N/A | |
Completed |
NCT01537575 -
Intravenous Immunoglobulins for Post-Polio Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT02089880 -
Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis
|
N/A | |
Completed |
NCT01402570 -
Glutathione and Health With Post-Polio Syndrome
|
N/A | |
Completed |
NCT00231439 -
Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)
|
Phase 2/Phase 3 |